Syon Capital LLC Has $630,000 Stock Position in Kenvue Inc. (NYSE:KVUE)

Syon Capital LLC grew its stake in Kenvue Inc. (NYSE:KVUE) by 78.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 29,276 shares of the company’s stock after purchasing an additional 12,865 shares during the quarter. Syon Capital LLC’s holdings in Kenvue were worth $630,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in the stock. CWM LLC raised its stake in Kenvue by 1,521.1% during the 3rd quarter. CWM LLC now owns 12,969 shares of the company’s stock worth $260,000 after buying an additional 12,169 shares during the period. AE Wealth Management LLC acquired a new stake in Kenvue during the 3rd quarter worth $619,000. IFP Advisors Inc acquired a new stake in Kenvue during the 3rd quarter worth $38,000. Global Retirement Partners LLC acquired a new stake in Kenvue during the 3rd quarter worth $28,000. Finally, SG Americas Securities LLC acquired a new stake in Kenvue during the 3rd quarter worth $1,062,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

KVUE has been the subject of a number of research reports. The Goldman Sachs Group initiated coverage on Kenvue in a report on Friday, March 1st. They set a “neutral” rating and a $20.00 target price for the company. William Blair initiated coverage on Kenvue in a report on Wednesday, April 3rd. They set a “market perform” rating for the company. Royal Bank of Canada lowered their target price on Kenvue from $25.00 to $24.00 and set an “outperform” rating for the company in a report on Friday, February 9th. JPMorgan Chase & Co. lowered their target price on Kenvue from $25.00 to $24.00 and set an “overweight” rating for the company in a report on Friday, February 9th. Finally, Sanford C. Bernstein initiated coverage on Kenvue in a report on Thursday, April 11th. They set an “underperform” rating and a $18.00 target price for the company. One research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $24.85.

Kenvue Stock Performance

KVUE traded down $0.16 during trading on Friday, reaching $18.86. 15,451,236 shares of the stock traded hands, compared to its average volume of 16,691,828. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.78 and a current ratio of 1.12. The stock’s 50-day moving average is $19.84 and its 200 day moving average is $20.14. Kenvue Inc. has a 12 month low of $17.82 and a 12 month high of $27.80.

Kenvue (NYSE:KVUE) last released its quarterly earnings data on Thursday, February 8th. The company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.03. The company had revenue of $3.67 billion for the quarter, compared to analysts’ expectations of $3.78 billion. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. On average, equities analysts predict that Kenvue Inc. will post 1.15 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, May 22nd. Investors of record on Wednesday, May 8th will be given a $0.20 dividend. The ex-dividend date of this dividend is Tuesday, May 7th. This represents a $0.80 annualized dividend and a yield of 4.24%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.